Vertex Pharmaceuticals, Inc. (VRTX)
|Net Income (ttm)||1.99B|
|Day's Range||182.88 - 187.15|
|52-Week Range||176.36 - 242.99|
|Price Target||258.45 (+40.8%)|
|Est. Earnings Date||Oct 28, 2021|
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitr... [Read more...]
In 2020, VRTX's revenue was $6.21 billion, an increase of 49.07% compared to the previous year's $4.16 billion. Earnings were $2.71 billion, an increase of 130.42%.Financial Statements
According to 28 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is 258.45, which is an increase of 40.83% from the latest price.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021 after the financial markets close. The compa...
The mean of analysts' price targets for Vertex (VRTX) points to a 42.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in...
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $185.49, marking a +0.04% move from the previous day.
Vertex announced promising trial data for its type 1 diabetes treatment candidate.
Vertex's (VRTX) single infusion drug candidate, VX-880, for type I diabetes shows restoration of insulin production and robust improvements in multiple measures in a phase I/II study
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North Americ...
BOSTON--(BUSINESS WIRE)--Vertex announced that five abstracts about its cystic fibrosis (CF) medicines will be presented at the 2021 North American Cystic Fibrosis Conference.
Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Nove...
BOSTON--(BUSINESS WIRE)--Vertex today announced positive data for the first patient from the Phase 1/2 clinical trial of VX-880, for the treatment of type-1 diabetes.
There are good reasons behind analysts' optimism about these stocks.
Vertex Pharmaceuticals (VRTX) closed at $181.34 in the latest trading session, marking a +0.63% move from the prior day.
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Balance risk and reward with these proven drugmakers.
One is at the beginning of its story. The others may enter new growth chapters down the road.
VRTX vs. PRTA: Which Stock Is the Better Value Option?
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $180.02, marking a -0.49% move from the previous day.
Should investors holding shares of Vertex Pharmaceuticals Incorporated ( VRTX , Financial) follow the axiom, “Good things come to those who wait?”